Skip Navigation LinksHome > January 3, 2003 - Volume 17 - Issue 1 > A V106M mutation in HIV-1 clade C viruses exposed to efavire...
Text sizing:
A
A
A
AIDS:
Fast Track

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

Brenner, Bluma; Turner, Dan; Oliveira, Maureen; Moisi, Daniela; Detorio, Mervi; Carobene, Mauricio; Marlink, Richard Ga,b; Schapiro, Jonathanc; Roger, Micheld; Wainberg, Mark A

Free Access
Article Outline
Collapse Box

Author Information

From the McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada, aHarvard School of Public Health, Boston, Massachusetts, USA, bBotswana-Harvard Laboratory, Gaborone, Botswana, the cDepartment of Medicine, Stanford University, Palo Alto, California, USA, and the dDépartement de Microbiologie et d’'Immunologie, Montreal, Quebec, Canada.

Correspondence to B. Brenner or M. Wainberg, McGill AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2.

Received: 30 September 2002; revised: 24 October 2002; accepted: 24 October 2002.

Collapse Box

Abstract

Objective: We have shown that HIV-1 clade C variants contain a valine codon 106 polymorphism (GTG) that facilitates a V106M transition (GTG←ATG) after selection with efavirenz (EFV). This study evaluates the prevalence of V106 (GTG) and 106M (ATG) codons in clinical isolates as well as the effects of V106M on resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI).

Methods: Genotypic analysis ascertained sequence diversity at codon 106, including both valine polymorphisms (GTA and GTG) and the V106A (GCA) and V106M (ATG) resistance-conferring mutations in B (n = 440) and non-B (n = 84) clinical isolates. Cell-based phenotypic assays were performed to determine the effects of V106M and V106A on levels of resistance to EFV, nevirapine and delavirdine.

Results: Most subtype B isolates harbored GTA (valine) at codon 106 (97% of cases) while the GTG (valine) polymorphism was generally present in clade C viruses (94% of cases). Under conditions of EFV but not nevirapine or delavirdine pressure (n = 8) in tissue culture, clade C isolates developed the V106M mutation (GTG←ATG), conferring high-level (100–1000-fold) cross-resistance to all NNRTI. Generation of V106M recombinant viruses by site-directed mutagenesis confirmed the ability of V106M to confer NNRTI cross-resistance. This mutation also developed in three of six EFV-treated patients harboring clade C infections. In current genotypic interpretative reports (including 15 algorithmic databases), V106A is listed as an nevirapine-specific mutation while V106M is not recognized.

Conclusions: V106M may be a signature mutation in clade C patients treated with EFV and may have the potential to confer high-level multi-NNRTI resistance.

Back to Top | Article Outline

Introduction

Highly active antiretroviral therapy with the three classes of antiretroviral drugs, namely nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTI and NNRTI) and protease inhibitors (PI) has helped to stabilize disease progression of predominantly subtype B infections in Western countries [1]. However, global epidemics with group M (non-B, A through J) and O clades in resource-poor nations are expanding and it is essential to develop effective management strategies for non-B clade infections [2,3]. Most commercialized drugs have been studied against clade B viruses and clade B reverse transcriptase (RT) and protease. To date, limited information is available on other subtypes in regard to virological or treatment response [3,4].

Efavirenz (EFV) given once daily in combination with two NRTI possesses potent antiviral activity [5]. Recent studies, including preliminary analysis of the ACTG 384 study suggest that a first-line regimen of choice is zidovudine (ZDV)/lamivudine (3TC)/EFV [6]. We have observed that resistance to EFV in clade C viruses can develop in vitro as a result of a V106M mutation that arises due to a natural GTG polymorphism at codon 106 in clade C variants, that is distinct from the nevirapine (NVP)-associated mutation at position 106 (i.e., V106A) commonly seen in clade B viruses [2,7]. The GTG polymorphism is largely limited to clade C viruses, yielding V106M in EFV-selected cells, while the naturally occurring codon in clade B viruses is GTA. We now show the prevalence of this GTG polymorphism in clinical isolates, the in vitro and in vivo evolution of EFV resistance in isolates carrying this polymorphism, and the consequences of V106M on responses to other NNRTI. We have also confirmed the significance of the V106M mutation by site-directed mutagenesis.

Back to Top | Article Outline

Subjects and methods

Study subjects and viral isolates

The clinical isolates in this study include subtype A (n = 29), B (n = 440), C (n = 39), D (n = 4), A/E (n = 3) and G (n = 9) variants. The RT region of plasma viral RNA from clinical samples was genotyped to ascertain viral subtype (clade) and to determine the nucleotide sequence at codon 106 [8]. Viruses were isolated from peripheral blood mononuclear cells (PBMC) of the three EFV-experienced patients who harbored the V106M mutation.

To ascertain the effect of the valine codon 106 polymorphism (GTG) on evolution of NNRTI drug resistance, viruses were amplified from clade C clinical isolates obtained from five treatment-naive subjects from Botswana and three treatment-naive Ethiopians [2]. Using serial passage in increasing concentrations of drugs, HIV-1 variants resistant to EFV and NVP were selected [6]. Recombinant clones carrying V106A or V106M were also constructed by cloning the BH10 polymerase gene into the pGEM-5Zf (+) vector (GIBCO-BRL Inc., Montreal, Canada) as described previously [9].

Back to Top | Article Outline
Genotypic and phenotypic resistance testing

Sequencing of extracted DNA was performed by Visible Genetics TruGene or by ABI technology to determine genotypic changes associated with drug resistance [10]. Scoring the presence and drug susceptibility of V106M viruses was performed using the Visible Genetics Inc., Virco Inc., Stanford, ABL, and geno2pheno algorithms [8,11–14].

Cell culture-based phenotypic assays were performed in cord blood mononuclear cells infected with recombinant, EFV-selected, or clinical clade C isolates to determine the extent to which antiretroviral drugs inhibited in vitro HIV-1 replication, as described previously [2,7]. The 50% drug inhibitory concentrations (IC50) for EFV, NVP, and delavirdine (DLV) were ascertained both pre- and post-selection with antiviral drugs.

Back to Top | Article Outline

Results

Prevalence of codon 106 substitutions in different clades

We determined the prevalence of the GTG polymorphism and V106M mutation in clinical isolates from the Montreal area. Whereas clade B isolates overwhelmingly expressed the valine GTA at codon 106 (97% of cases), clade C isolates carried the valine GTG (94% of cases) (Fig. 1). Subtypes, other than for clade C, generally expressed the GTA nucleotide sequence at codon 106, although one case each of subtypes D and G also expressed GTG (Fig. 1). Whereas, the V106A or V106I mutations rarely developed in clade B infections, the V106M mutation was observed in three of six clade C persons treated with EFV/d4T/3TC or EFV/ZDV/3TC. In one female, elevated viremia (3000 copies/ml) was associated with V106M and M184V; in the other two females with viremia of 10 241 and 19 363 copies/ml, 106M and K103N were present alone or with T215Y.

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline
Emergence of V106M in isolates with the GTG polymorphism

To establish the consequences of the GTG substitution and V106M mutation on NNRTI resistance profiles, clade C clinical isolates from eight treatment-naive persons were selected for NVP and EFV resistance in tissue culture (Table 1). In all selections with EFV, V106M was observed to arise. In contrast, V106M never arose when the same clade C isolates were subjected to NVP. Similarly, V106M never arose under pressure with DLV [7]. In the case of the clade C viruses, the presence of V106M was followed by Y188H or Y188C if selection pressure with EFV was continued.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
Phenotypic susceptibility of V106M viral isolates

The drug susceptibility of three of the in vitro EFV-selected isolates harboring V106M is shown in Table 2. All viruses harboring V106M following selection with EFV showed high-level cross-resistance to all approved NNRTI. This included two EFV-selected isolates in which V106M was the only NNRTI mutation present (Table 2).

Table 2
Table 2
Image Tools

Viruses isolated from the PBMC of the three EFV-treated individuals harboring V106M were also evaluated for NNRTI drug susceptibility. As depicted in Fig. 2, the patient harboring V106M as the only NNRTI mutation showed resistance to EFV, NVP, and DLV. These data confirm that V106M confers high-level cross-resistance to all NNRTI. The remaining two patients also showed NNRTI resistance although these isolates also harbored the K103N mutation (Fig. 2). The cross-resistance observed with V106M variants selected either in vitro or in vivo, is in the range observed for K103N and Y188C/H/L in clade B or C infections (Table 2, Fig. 2).

Fig. 2
Fig. 2
Image Tools

Site-directed mutagenesis was performed to introduce the V106M mutation into the subtype B infectious recombinant virus, BH10. This virus possessed a phenotypic pattern consistent with high-level cross-resistance to all approved NNRTI (Table 2). In contrast, the V106A mutation introduced into BH10 yielded resistance only to NVP, consistent with previous observations (Table 2, Fig. 2) [8,11].

Sequences of viral variants harboring V106M as a sole NNRTI resistance-associated mutation were entered into a number of sequence databases. Three clinical isolates sequenced by ABI and sent for Virco Virtual phenotypic analysis did not score the V106M mutation. While the Visible Genetics interpretative system did report V106M as an unexpected mutation, the Trugene algorithm predicted sensitivity to all NNRTI. In five of six Stanford algorithms, the five ABL databases, the Los Alamos and IAS-USA databases, the V106M mutation was not scored [8,11–14]. The Stanford Specialty and geno2pheno algorithms scored V106M as resistance to NVP with sensitivity to both EFV and DLV [8,13]. Thus, no currently available algorithmic database recognizes V106M as a mutation conferring NNRTI cross-resistance.

Back to Top | Article Outline

Discussion

The rapid expansion of new HIV-1 subtypes poses new challenges in HIV-1 disease management. To date, limited information is available on the efficacy of antiretroviral drugs and the emergence of drug resistance among genotypically diverse non-B viral subtypes. Our study has identified a novel multi-NNRTI resistance mutation that may develop in clade C infections after EFV treatment. The valine polymorphism at codon 106 (GTG) in clade C variants favors occurrence of a V106M (GTG←ATG) mutation following either in vitro or in vivo exposure to EFV. This GTG polymorphism that is present in 94% of clade C isolates was observed rarely in clade B variants (1.5% of cases) (Fig. 1). V106M arose in three of six persons with clade C infections who were treated with EFV, but was seen at an incidence of < 0.6 % in NNRTI-treated clade B infections.

Several studies have suggested that viral subtype does not generally influence antiretroviral response to NRTI or PI [3,4,15–19], but that non-B clade viruses may respond to NNRTI differently than do clade B variants [20]. Both HIV-2 viruses and clade O viruses show innate resistance to all NNRTI due to the presence of naturally occurring Y181I and Y181C in RT, respectively [2]. It is interesting that V106M only arose with EFV whereas Y181C was the favored mutation selected with NVP. It has been reported that Y181C is more replicatively fit than V106A in clade B isolates [20]. Further studies are required to determine the relative drug susceptibility and fitness of NNRTI mutations in different clade backbones.

The principal resistance mutations associated with multi-NNRTI resistance in clade B infections are Y188C and K103N [20,21]. When clade C viruses were serially passaged in the presence of high doses of EFV, Y188H developed in addition to V106M. The Y188H mutation has been previously observed for subtype B viruses exposed to two experimental NNRTI, loviride and TIBO R82913 [11]. In addition to V106M, the K103N resistance mutation arose in two of three individuals with clade C viruses who were treated with EFV.

V106M has not been reported as a mutation conferring resistance to NNRTI by any resistance database. While V106A/I has been described in clade B infections, resistance profiles predict resistance to NVP but sensitivity to DLV and EFV. These findings underscore the limitations of genotypic interpretative reports that fail to include polymorphisms or clade designation. Although these considerations may add complexity to reports, they will also allow easier retrospective analysis of resistance mutations that may arise in non-B HIV infections. At present, only Visible Genetics, ABL and geno2pheno software provide detailed analyses of polymorphisms, and while the Virco Virtual Phenotype provides clade designation, reports from Visible Genetics do not.

Inexpensive treatment strategies for developing countries are urgently required. Both NVP and EFV are drugs of choice given their efficacy and potential for single daily dosing. The emergence of V106M in patients harboring clade C infections will be a matter of concern if cross-resistance to all approved NNRTI will be shown to occur as a result of this mutation. Physicians should be aware of the V106M mutation and its potential impact on virological responsiveness.

Back to Top | Article Outline

Acknowledgements

Sponsorship: This work was sponsored by the Canadian Institutes for Health Research (CIHR), the Canadian Foundation for AIDS research (CANFAR), Fonds de la Recherche en Santé du Québec (FRSQ), and by the Secure the Future Programme of Bristol-Myers Squibb, Inc.

Back to Top | Article Outline

References

1.Pallela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853–860.

2.Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of HIV-1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002, 46:2087–2094.

3.Loemba H, Wainberg MA, Brenner BG. Effects of HIV-1 clade diversity on HIV-1 virulence and antiretroviral drug sensitivity. Recent Rev Devel Virol 2001, 3:121–129.

4.Pillay D, Walker AS, Gibb DM, de Rossi S, Kaye M, Ait-Khaled M, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002, 186: 617–625.

5.Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865–1872.

6.Robbins G, Shafer R, Smeaton L, de Grottola V, Pettinelli C, Synder S, et al. Antiretroviral strategies in naive HIV+ subjects: comparisons of sequential 3-drug regimens (ACTG 384). Program and abstracts of the XIV International Conference on AIDS. Barcelona, July 7–12, 2002 [abstract LbOr20A].

7.Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of drug resistance. Antiviral Res 2002, 56:129–142.

8.Shafer RW, Gonzales MJ, Brun-Vezinet F. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antiviral Ther 2001, 6 (suppl 1):101.

9.Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992, 66:7128–7135.

10.Salomon H, Wainberg MA, Brenner BG, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use. AIDS 2000, 14:F17–F23.

11.Hammond J, Larder BA, Schinasi RF, Mellors JW. Mutations in retroviral genes associated with drug resistance. http://www.hiv. lanl.gov/HTML/reviews/Mellors.html

12.Advanced Biological Laboratories Website. http://www.ablnet works.com

13.Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci, USA 2002, 99:8271–8276.

14.D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Topics in HIV Med 2002, 10:21–25.

15.Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001, 15:1493–1502.

16.Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1999, 14:157–162.

17.Caride E, Hertogs K, Larder B, Dehertogh P, Brindeiro R, Machado E, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in individuals failing HAART. Virus Genes 2001, 23:193–202.

18.Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000, 275:107–115.

19.Loveday C, van Hooff F, Johnson M. Inferior virological response to highly active antiretroviral therapy in patients with HIV-1 subtype C infection: a case controlled study. Antiviral Ther 2002, 7:S145.

20.Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, et al. Mutants of human immunodeficiency virus type (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RnaseH cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000, 74:8390–8401.

21.Bacheler LT, Anton ED, Kudish, P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44:2475–2684.

Cited By:

This article has been cited 96 time(s).

Antimicrobial Agents and Chemotherapy
Mutation D30N is not preferentially selected by human immunodeficiency virus type I subtype C in the development of resistance to nelfinavir
Grossman, Z; Paxinos, EE; Averbuch, D; Maayan, S; Parkin, NT; Engelhard, D; Lorber, M; Istomin, V; Shaked, Y; Mendelson, E; Ram, D; Petropoulos, CJ; Schapiro, JM
Antimicrobial Agents and Chemotherapy, 48(6): 2159-2165.
10.1128/AAC.48.6.2159-2165.2004
CrossRef
AIDS
HIV-1 subtype distribution and the problem of drug resistance
Wainberg, MA
AIDS, 18(): S63-S68.
10.1097/01.aids.0000131319.67773.8e
CrossRef
Antimicrobial Agents and Chemotherapy
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
Snoeck, J; Kantor, R; Shafer, RW; Van Laethem, K; Deforche, K; Carvalho, AP; Wynhoven, B; Soares, MA; Cane, P; Clarke, J; Pillay, C; Sirivichayakul, S; Ariyoshi, K; Holguin, A; Rudich, H; Rodrigues, R; Bouzas, MB; Brun-Vezinet, F; Reid, C; Cahn, P; Brigido, LF; Grossman, Z; Soriano, V; Sugiura, W; Tanuri, A; Harrigan, RP; Camacho, R; Schapiro, JM; Katzenstein, D; Vandamme, AM
Antimicrobial Agents and Chemotherapy, 50(2): 694-701.
10.1128/AAC.50.2.694-701.2006
CrossRef
Journal of Virology
Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers
Held, DM; Kissel, JD; Thacker, SJ; Michalowski, D; Saran, D; Ji, JF; Hardy, RW; Rossi, JJ; Burke, DH
Journal of Virology, 81(): 5375-5384.
10.1128/JVI.01923-06
CrossRef
Journal of Virological Methods
A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand
Poonpiriya, V; Sungkanuparph, S; Leechanachai, P; Pasomsub, E; Watitpun, C; Chunhakan, S; Chantratita, W
Journal of Virological Methods, 151(1): 79-86.
10.1016/j.jviromet.2008.03.017
CrossRef
Infection Genetics and Evolution
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure
Dumans, AT; Barreto, CC; Santos, AF; Arruda, M; Sousa, TM; Machado, ES; Sabino, EC; Brindeiro, RM; Tanuri, A; Duarte, AJ; Soares, MA
Infection Genetics and Evolution, 9(1): 62-70.
10.1016/j.meegid.2008.10.002
CrossRef
Clinical Infectious Diseases
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
Hirsch, MS; Gunthard, HF; Schapiro, JM; Brun-Vezinet, F; Clotet, B; Hammer, SM; Johnson, VA; Kuritzkes, DR; Mellors, JW; Pillay, D; Yeni, PG; Jacobsen, DM; Richman, DD
Clinical Infectious Diseases, 47(2): 266-285.
10.1086/589297
CrossRef
Antiviral Therapy
Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India
Vidya, M; Saravanan, S; Uma, S; Kumarasamy, N; Sunil, SS; Kantor, R; Katzenstein, D; Ramratnam, B; Mayer, KH; Suniti, S; Balakrishnan, P
Antiviral Therapy, 14(7): 1005-1009.
10.3851/IMP1411
CrossRef
AIDS Research and Human Retroviruses
HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, Brazil
Munerato, P; Sucupira, MC; Oliveros, MPR; Janini, LM; de Souza, DF; Pereira, AA; Inocencio, LA; Diaz, RS
AIDS Research and Human Retroviruses, 26(3): 265-273.
10.1089/aid.2009.0288
CrossRef
Journal of Antimicrobial Chemotherapy
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G
Santos, AF; Abecasis, AB; Vandamme, AM; Camacho, RJ; Soares, MA
Journal of Antimicrobial Chemotherapy, 63(3): 593-599.
10.1093/jac/dkn526
CrossRef
Plos One
Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
Soares, EAJM; Santos, AFA; Sousa, TM; Sprinz, E; Martinez, AMB; Silveira, J; Tanuri, A; Soares, MA
Plos One, 2(8): -.
ARTN e730
CrossRef
AIDS Reviews
Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes
Holguin, A; de Arellano, ER; Rivas, P; Soriano, V
AIDS Reviews, 8(2): 98-107.

Antiviral Research
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
Martinez, J; Coplan, P; Wainberg, MA
Antiviral Research, 71(): 343-350.
10.1016/j.antiviral.2006.05.013
CrossRef
Microbes and Infection
Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique
Parreira, R; Piedade, J; Domingues, A; Lobao, D; Santos, M; Venenno, T; Baptista, JL; Mussa, SAS; Barreto, ATL; Baptista, AJ; Esteves, A
Microbes and Infection, 8(): 2442-2451.
10.1016/j.micinf.2006.05.005
CrossRef
Journal of Clinical Virology
No response to first-line tenofovir plus lamivudine plus efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs
Van Laethem, K; De Munter, P; Schrooten, Y; Verbesselt, R; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM
Journal of Clinical Virology, 39(1): 43-47.
10.1016/j.jcv.2007.02.003
CrossRef
AIDS Research and Human Retroviruses
Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain
De Mendoza, C; Garrido, C; Poveda, E; Corral, A; Zahonero, N; Trevino, A; Anta, L; Soriano, V
AIDS Research and Human Retroviruses, 25(): 967-972.
10.1089/aid.2008.0166
CrossRef
Clinical Infectious Diseases
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS Society-USA panel
Hirsch, MS; Brun-Vezinet, F; Clotet, B; Conway, B; Kuritzkes, DR; D'Aquila, RT; Demeter, LM; Hammer, SM; Johnson, VA; Loveday, C; Mellors, JW; Jacobsen, DM; Richman, DD
Clinical Infectious Diseases, 37(1): 113-128.

AIDS Research and Human Retroviruses
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C
Quan, YD; Brenner, BG; Marlink, RG; Essex, M; Kurimura, T; Wainberg, MA
AIDS Research and Human Retroviruses, 19(9): 743-753.

Antimicrobial Agents and Chemotherapy
Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing
Rhee, SY; Liu, T; Ravela, J; Gonzales, MJ; Shafer, RW
Antimicrobial Agents and Chemotherapy, 48(8): 3122-3126.
10.1128/AAC.48.8.3122-3126.2004
CrossRef
Antiviral Therapy
Updated European recommendations for the clinical use of HIV drug resistance testing
Vandamme, AM; Sonnerborg, A; Ait-Khaled, M; Albert, J; Asjo, B; Bacheler, L; Banhegyi, D; Boucher, C; Brun-Vezinet, F; Camacho, R; Clevenbergh, P; Clumeck, N; Dedes, N; De Luca, A; Doerr, HW; Faudon, JL; Gatti, G; Gerstoft, J; Hall, WW; Hatzakis, A; Hellmann, N; Horban, A; Lundgren, JD; Kempf, D; Miller, M; Miller, V; Myers, TW; Nielsen, C; Opravil, M; Palmisano, L; Perno, CF; Phillips, A; Pillay, D; Pumarola, T; Ruiz, L; Salminen, M; Schapiro, J; Schmidt, B; Schmit, JC; Schuurman, R; Shulse, E; Soriano, V; Staszewski, S; Vella, S; Youle, M; Ziermann, R; Perrin, L
Antiviral Therapy, 9(6): 829-848.

Expert Opinion on Drug Metabolism & Toxicology
Efavirenz - Still first-line king?
Best, BM; Goicoechea, M
Expert Opinion on Drug Metabolism & Toxicology, 4(7): 965-972.
10.1517/17425250802204217
CrossRef
Journal of Neurovirology
NeuroAIDS in Brazil
Ellis, RJ; Joseph, J; de Almeida, SM
Journal of Neurovirology, 13(2): 89-96.
10.1080/13550280601132074
CrossRef
Clinical Infectious Diseases
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa
Marconi, VC; Sunpath, H; Lu, Z; Gordon, M; Koranteng-Apeagyei, K; Hampton, J; Carpenter, S; Giddy, J; Ross, D; Holst, H; Losina, E; Walker, BD; Kuritzkes, DR
Clinical Infectious Diseases, 46(): 1589-1597.
10.1086/587109
CrossRef
AIDS Research and Human Retroviruses
Antiretroviral Drug-Resistant Mutations at Baseline and at Time of Failure of Antiretroviral Therapy in HIV Type 1-Coinfected TB Patients
Rajesh, L; Karunaianantham, R; Narayanan, PR; Swaminathan, S
AIDS Research and Human Retroviruses, 25(): 1179-1185.
10.1089/aid.2009.0110
CrossRef
Clinical and Investigative Medicine-Medecine Clinique Et Experimentale
Is there any hope for AIDS?
Wainberg, MA
Clinical and Investigative Medicine-Medecine Clinique Et Experimentale, 27(1): 51-58.

Jaids-Journal of Acquired Immune Deficiency Syndromes
Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing
Hsu, RK; Wainberg, MA
Jaids-Journal of Acquired Immune Deficiency Syndromes, 35(): S13-S21.

Journal of Clinical Microbiology
Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
Covens, K; Dekeersmaeker, N; Schrooten, Y; Weber, J; Schols, D; Quinones-Mateu, ME; Vandamme, AM; Van Laethem, K
Journal of Clinical Microbiology, 47(7): 2232-2242.
10.1128/JCM.01739-08
CrossRef
Brazilian Journal of Infectious Diseases
Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil
Medeiros, MS; Arruda, EAG; Guerrant, RL; Brown, CC; Lima, AAM
Brazilian Journal of Infectious Diseases, 11(5): 451-455.

AIDS Research and Human Retroviruses
Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection
Ntemgwa, M; Gill, MJ; Brenner, BG; Moisi, D; Wainberg, MA
AIDS Research and Human Retroviruses, 24(7): 995-1002.
10.1089/aid.2008.0064
CrossRef
Epidemiology and Infection
HIV subtypes in Scotland, 2000-2006
Yirrell, DL; Shaw, L; Campbell, E; Burns, SM; Cameron, SO; Goldberg, D
Epidemiology and Infection, 136(8): 1069-1075.
10.1017/S0950268807009545
CrossRef
AIDS Research and Human Retroviruses
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1
Richard, N; Juntilla, M; Abraha, A; Demers, K; Paxinos, E; Galovich, J; Petropoulos, C; Whalen, CC; Kyeyune, F; Atwine, D; Kityo, C; Mugyenyi, P; Arts, EJ
AIDS Research and Human Retroviruses, 20(4): 355-364.

Hiv Medicine
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
Gazzard, B
Hiv Medicine, 6(): 1-61.

AIDS Reviews
HIV-1 Genotypic Drug Resistance Interpretation Rules-2009 Spanish Guidelines
de Mendoza, C; Anta, L; Garcia, F; Perez-Elias, J; Gutierrez, F; Llibre, JM; Menendez-Arias, L; Dalmau, D; Soriano, V
AIDS Reviews, 11(1): 39-51.

Expert Review of Anti-Infective Therapy
Trends in the European HIV/AIDS epidemic: a perspective from Italy
Madeddu, G; Rezza, G; Mura, MS
Expert Review of Anti-Infective Therapy, 7(1): 25-36.
10.1586/14787210.7.1.25
CrossRef
National Institute of Allergy and Infectious Diseases, Nih, Vol 1: Frontiers in Research
Biological Basis and Clinical Significance of HIV Resistance to Antiviral Drugs
Wainberg, MA; Schader, S
National Institute of Allergy and Infectious Diseases, Nih, Vol 1: Frontiers in Research, (): 309-+.

Journal of Virology
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
Hachiya, A; Kodama, EN; Sarafianos, SG; Schuckmann, MM; Sakagami, Y; Matsuoka, M; Takiguchi, M; Gatanaga, H; Oka, S
Journal of Virology, 82(7): 3261-3270.
10.1128/JVI.01154-07
CrossRef
AIDS Research and Human Retroviruses
The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa
Novitsky, V; Wester, CW; DeGruttola, V; Bussmann, H; Gaseitsiwe, S; Thomas, A; Moyo, S; Musonda, R; Van Widenfelt, E; Marlink, RG; Essex, M
AIDS Research and Human Retroviruses, 23(7): 868-878.
10.1089/aid.2006.0298
CrossRef
AIDS Research and Human Retroviruses
Resistance mutations in subtype CHIV type 1 isolates from Indian patients of mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR
Deshpande, A; Jauvin, V; Magnin, N; Pinson, P; Faure, M; Masquelier, B; Aurillac-Lavignolle, V; Fleury, HJ
AIDS Research and Human Retroviruses, 23(2): 335-340.
10.1089/aid.2006.0183
CrossRef
Plos Medicine
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration
Kantor, R; Katzenstein, DA; Efron, B; Carvalho, AP; Wynhoven, B; Cane, P; Clarke, J; Sirivichayakul, S; Soares, MA; Snoeck, J; Pillay, C; Rudich, H; Rodrigues, R; Holguin, A; Ariyoshi, K; Bouzas, MB; Cahn, P; Sugiura, W; Soriano, V; Brigido, LF; Grossman, Z; Morris, L; Vandamme, AM; Tanuri, A; Phanuphak, P; Weber, JN; Pillay, D; Harrigan, PR; Camacho, R; Schapiro, JM; Shafer, RW
Plos Medicine, 2(4): 325-337.
ARTN e112
CrossRef
Antimicrobial Agents and Chemotherapy
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1
Turner, D; Brenner, B; Moisi, D; Detorio, M; Cesaire, R; Kurimura, T; Mori, H; Essex, M; Maayan, S; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 48(8): 2993-2998.
10.1128/AAC.48.8.2933-2998.2004
CrossRef
Antimicrobial Agents and Chemotherapy
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen
Doualla-Bell, F; Avalos, A; Gaolathe, T; Mine, M; Gaseitsiwe, S; Ndwapi, N; Novitsky, VA; Brenner, B; Oliveira, M; Moisi, D; Moffat, H; Thior, I; Essex, M; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 50(6): 2210-2213.
10.1128/AAC.01447-05
CrossRef
Journal of Clinical Virology
Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes
Covens, K; Kabeya, K; Schrooten, Y; Dekeersmaeker, N; Van Wijngaerden, E; Vandamme, AM; De Wit, S; Van Laethem, K
Journal of Clinical Virology, 44(4): 325-328.
10.1016/j.jcv.2009.01.012
CrossRef
Annals of Pharmacotherapy
Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents
Adams, J; Patel, N; Mankaryous, N; Tadros, M; Miller, CD
Annals of Pharmacotherapy, 44(1): 157-165.
10.1345/aph.1M359
CrossRef
AIDS
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine
Morris, L; Pillay, C; Chezzi, C; Lupondwana, P; Ntsala, M; Levin, L; Venter, F; Martinson, N; Gray, G; McIntyre, J
AIDS, 17(): 1698-1700.
10.1097/01.aids.0000076295.76477.6c
CrossRef
Jaids-Journal of Acquired Immune Deficiency Syndromes
HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors
Wainberg, MA
Jaids-Journal of Acquired Immune Deficiency Syndromes, 34(): S2-S7.

Virology
Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives
Huang, L; Yuan, X; Yu, DL; Lee, KH; Chen, CH
Virology, 332(2): 623-628.
10.1016/j.virol.2004.11.033
CrossRef
Journal of Medical Virology
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso
Nadembega, WM; Giannella, S; Simpore, J; Ceecherini-Silberstein, F; Pietra, V; Bertoli, A; Pignatelli, S; Bellocchi, MC; Nikiema, JB; Cappelli, G; Bere, A; Colizzi, V; Perno, CP; Musumeci, S
Journal of Medical Virology, 78(): 1385-1391.
10.1002/jmv.20709
CrossRef
Journal of Antimicrobial Chemotherapy
Efavirenz: a decade of clinical experience in the treatment of HIV
Maggiolo, F
Journal of Antimicrobial Chemotherapy, 64(5): 910-928.
10.1093/jac/dkp334
CrossRef
AIDS Research and Human Retroviruses
HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy
Pillay, V; Pillay, C; Kantor, R; Venter, F; Levin, L; Morris, L
AIDS Research and Human Retroviruses, 24(): 1449-1454.
10.1089/aid.2008.0180
CrossRef
AIDS Reviews
Role of Genetic Diversity amongst HIV-1 Non-B Subtypes in Drug Resistance: A Systematic Review of Virologic and Biochemical Evidence
Martinez-Cajas, JL; Pant-Pai, N; Klein, MB; Wainberg, MA
AIDS Reviews, 10(4): 212-223.

Antimicrobial Agents and Chemotherapy
HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes
Lisovsky, I; Schader, SM; Martinez-Cajas, JL; Oliveira, M; Moisi, D; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 54(7): 2878-2885.
10.1128/AAC.01828-09
CrossRef
Journal of Infectious Diseases
Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance
Dumans, AT; Soares, MA; Machado, ES; Hue, S; Brindeiro, RM; Pillay, D; Tanuri, A
Journal of Infectious Diseases, 189(7): 1232-1238.

Antiviral Therapy
Antiretroviral drug resistance in non-subtype BHIV-1, HIV-2 and SIV
Parkin, NT; Schapiro, JM
Antiviral Therapy, 9(1): 3-12.

Antiviral Research
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009)
de Bethune, MP
Antiviral Research, 85(1): 75-90.
10.1016/j.antiviral.2009.09.008
CrossRef
Antimicrobial Agents and Chemotherapy
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
Diallo, K; Brenner, B; Oliveira, M; Moisi, D; Detorio, M; Gotte, M; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 47(7): 2376-2379.
10.1128/AAC.47.7.2376-2379.2003
CrossRef
Journal of Virology
Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors
Gao, Y; Paxinos, E; Galovich, J; Troyer, R; Baird, H; Abreha, M; Kityo, C; Mugyenyi, P; Petropoulos, C; Arts, EJ
Journal of Virology, 78(): 5390-5401.
10.1128/JVI.78.10.5390-5401.2004
CrossRef
Chemistry & Biodiversity
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future
De Clercq, E
Chemistry & Biodiversity, 1(1): 44-64.

AIDS Research and Human Retroviruses
Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba
Perez, L; Alvarez, LP; Carmona, R; Aragones, C; Delgado, E; Thomson, MM; Gonzalez, Z; Contreras, G; Perez, J; Najera, R
AIDS Research and Human Retroviruses, 23(3): 407-414.
10.1089/aid.2006.0155
CrossRef
Journal of Clinical Microbiology
Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major Drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B
Ndembi, N; Abraha, A; Pilch, H; Ichimura, H; Mbanya, D; Kaptue, L; Salata, R; Arts, EJ
Journal of Clinical Microbiology, 46(1): 177-184.
10.1128/JCM.00428-07
CrossRef
Current Opinion in Investigational Drugs
Microbicides for multidrug-resistant and multitropic HIV-1
D'Cruz, OJ; Uckun, FM
Current Opinion in Investigational Drugs, 9(2): 152-169.

Antiviral Therapy
Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1CRF02_AG and AGK subtypes in Mali and Burkina Faso
Sylla, M; Chamberland, A; Boileau, C; Traore, HA; Ag-Aboubacrine, S; Cisse, M; Koala, S; Drabo, J; Diallo, I; Niamba, P; Trembloy-Sher, D; Machouf, N; Rashed, S; Nickle, DC; Nguyen, VK; Tremblay, CL
Antiviral Therapy, 13(1): 141-148.

Journal of Antimicrobial Chemotherapy
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006
Derache, A; Maiga, AI; Traore, O; Akonde, A; Cisse, M; Jarrousse, B; Koita, V; Diarra, B; Carcelain, G; Barin, F; Pizzocolo, C; Pizarro, L; Katlama, C; Calvez, V; Marcelin, AG
Journal of Antimicrobial Chemotherapy, 62(3): 456-463.
10.1093/jac/dkn234
CrossRef
Journal of Infectious Diseases
Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV-1 Subtype C
Invernizzi, CF; Coutsinos, D; Oliveira, M; Moisi, D; Brenner, BG; Wainberg, MA
Journal of Infectious Diseases, 200(8): 1202-1206.
10.1086/605894
CrossRef
Journal of Clinical Virology
Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients
Carmona, R; Perez-Alvarez, L; Munoz, M; Casado, G; Delgado, E; Sierra, M; Thomson, M; Vega, Y; de Parga, EV; Contreras, G; Medrano, L; Najera, R
Journal of Clinical Virology, 32(3): 248-253.
10.1016/j.jcv.2004.11.009
CrossRef
Journal of Virology
Minireview - Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications
Buonaguro, L; Tornesello, ML; Buonaguro, FA
Journal of Virology, 81(): 10209-10219.
10.1128/JVI.00872-07
CrossRef
AIDS Research and Human Retroviruses
Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs
Kissel, JD; Held, DM; Hardy, RW; Burke, DH
AIDS Research and Human Retroviruses, 23(5): 699-708.
10.1089/aid.2006.0262
CrossRef
Antimicrobial Agents and Chemotherapy
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
Parkin, NT; Hellmann, NS; Whitcomb, JM; Kiss, L; Chappey, C; Petropoulos, CJ
Antimicrobial Agents and Chemotherapy, 48(2): 437-443.
10.1128/AAC.48.2.437-443.2004
CrossRef
AIDS Reviews
Characterization and Structural Analysis of HIV-1 Integrase Conservation
Ceccherini-Silberstein, F; Malet, I; D'Arrigo, R; Antinori, A; Marcelin, AG; Perno, CF
AIDS Reviews, 11(1): 17-29.

Lancet Infectious Diseases
Approach to salvage antiretroviral therapy in heavily anti retroviral-experienced HIV-positive adults
Temesgen, Z; Cainelli, F; Poeschla, EM; Vlahakis, SAR; Vento, S
Lancet Infectious Diseases, 6(8): 496-507.

Labmedicine
Clinical significance of HIV-1 drug resistance mutations
Wagner, TA; Frenkel, LM
Labmedicine, 37(9): 554-561.
10.1309/UCH8A9GR5KAO1VPU
CrossRef
Medicinal Research Reviews
Nem developments in natural products-based anti-AIDS research
Yu, DL; Morris-Natschke, SL; Lee, KH
Medicinal Research Reviews, 27(1): 108-132.
10.1002/med.20075
CrossRef
Future Virology
Impact of genetic variation of HIV-1 on drug resistance development
Snoeck, J; Vandamme, AM; Camacho, RJ
Future Virology, 2(3): 303-310.
10.2217/17460794.2.3.303
CrossRef
Antiviral Therapy
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies
Shafer, RW; Rhee, SY; Bennett, DE
Antiviral Therapy, 13(): 59-68.

Antimicrobial Agents and Chemotherapy
Development of an Allele-Specific PCR for Detection of the K65R Resistance Mutation in Patients Infected with Subtype C Human Immunodeficiency Virus Type 1
Toni, TA; Brenner, BG; Asahchop, EL; Ntemgwa, M; Moisi, D; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 54(2): 907-911.
10.1128/AAC.01080-09
CrossRef
AIDS Research and Human Retroviruses
Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE
Maljkovic, I; Wilbe, K; Solver, E; Alaeus, A; Leitner, T
AIDS Research and Human Retroviruses, 19(): 989-997.

Journal of Infectious Diseases
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
Eshleman, SH; Hoover, DR; Chen, S; Hudelson, SE; Guay, LA; Mwatha, A; Fiscus, SA; Mmiro, F; Musoke, P; Jackson, JB; Kumwenda, N; Taha, T
Journal of Infectious Diseases, 192(1): 30-36.

AIDS Research and Human Retroviruses
Confronting the emergence of drug-resistant HIV type 1: Impact of antiretroviral therapy on individual and population resistance
Daar, ES; Richman, DD
AIDS Research and Human Retroviruses, 21(5): 343-357.

Cold Spring Harbor Perspectives in Medicine
HIV-1 Antiretroviral Drug Therapy
Arts, EJ; Hazuda, DJ
Cold Spring Harbor Perspectives in Medicine, 2(4): -.
ARTN a007161
CrossRef
Virology
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance
Delviks-Frankenberry, KA; Lengruber, RB; Santos, AF; Silveira, JM; Soares, MA; Kearney, MF; Maldarelli, F; Pathak, VK
Virology, 435(2): 433-441.
10.1016/j.viro1.2012.09.021
CrossRef
Plos One
Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes
Charpentier, C; Lambert-Niclot, S; Alteri, C; Storto, A; Flandre, P; Svicher, V; Perno, F; Brun-Vezinet, F; Calvez, V; Marcelin, AG; Ceccherini-Silberstein, F; Descamps, D
Plos One, 8(1): -.
ARTN e54381
CrossRef
Current Opinion in Virology
The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
Gotte, M
Current Opinion in Virology, 2(5): 644-650.
10.1016/j.coviro.2012.08.004
CrossRef
Retrovirology
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Abecasis, AB; Wensing, AMJ; Paraskevis, D; Vercauteren, J; Theys, K; de Vijver, DAMCV; Albert, J; Asjo, B; Balotta, C; Beshkov, D; Camacho, RJ; Clotet, B; De Gascun, C; Griskevicius, A; Grossman, Z; Hamouda, O; Horban, A; Kolupajeva, T; Korn, K; Kostrikis, LG; Kucherer, C; Liitsola, K; Linka, M; Nielsen, C; Otelea, D; Paredes, R; Poljak, M; Puchhammer-Stockl, E; Schmit, JC; Sonnerborg, A; Stanekova, D; Stanojevic, M; Struck, D; Boucher, CAB; Vandamme, AM
Retrovirology, 10(): -.
ARTN 7
CrossRef
Journal of Antimicrobial Chemotherapy
Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors
Koning, FA; Castro, H; Dunn, D; Tilston, P; Cane, PA; Mbisa, JL
Journal of Antimicrobial Chemotherapy, 68(6): 1220-1236.
10.1093/jac/dkt012
CrossRef
AIDS
Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa
Barth, RE; Wensing, AM; Tempelman, HA; Moraba, R; Schuurman, R; Hoepelman, AI
AIDS, 22(16): 2210-2212.
10.1097/QAD.0b013e328313bf87
PDF (277) | CrossRef
AIDS
Bayesian network analyses of resistance pathways against efavirenz and nevirapine
Deforche, K; Camacho, RJ; Grossman, Z; Soares, MA; Van Laethem, K; Katzenstein, DA; Harrigan, PR; Kantor, R; Shafer, R; Vandamme, A; on behalf of the non-B workgroup,
AIDS, 22(16): 2107-2115.
10.1097/QAD.0b013e32830fe940
PDF (679) | CrossRef
AIDS
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C
Schapiro, JM; for the Israel AIDS Multi-Center Study Group, ; Grossman, Z; Istomin, V; Averbuch, D; Lorber, M; Risenberg, K; Levi, I; Chowers, M; Burke, M; Yaacov, NB
AIDS, 18(6): 909-915.

PDF (91)
AIDS
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Brenner, BG; Oliveira, M; Doualla-Bell, F; Moisi, DD; Ntemgwa, M; Frankel, F; Essex, M; Wainberg, MA
AIDS, 20(9): F9-F13.
10.1097/01.aids.0000232228.88511.0b
PDF (200) | CrossRef
AIDS
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes
for the International Non Subtype B HIV-1 Working Group, ; Rhee, S; Kantor, R; Katzenstein, DA; Camacho, R; Morris, L; Sirivichayakul, S; Jorgensen, L; Brigido, LF; Schapiro, JM; Shafer, RW
AIDS, 20(5): 643-651.
10.1097/01.aids.0000216363.36786.2b
PDF (709) | CrossRef
Current Opinion in Infectious Diseases
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing
De Luca, A; Perno, C
Current Opinion in Infectious Diseases, 16(6): 573-580.

PDF (104)
Current Opinion in Infectious Diseases
Impact of HIV-1 pol diversity on drug resistance and its clinical implications
Kantor, R
Current Opinion in Infectious Diseases, 19(6): 594-606.
10.1097/QCO.0b013e3280109122
PDF (215) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Characterization of Mutations in CRF01_AE Virus Isolates From Antiretroviral Treatment-Naive and -Experienced Patients in Singapore
Hsu, L; Subramaniam, R; Bacheler, L; Paton, NI
JAIDS Journal of Acquired Immune Deficiency Syndromes, 38(1): 5-13.

PDF (109)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Study of Antiretroviral Drug–Resistant HIV-1 Genotypes in Northern Thailand: Role of Mutagenically Separated Polymerase Chain Reaction as a Tool for Monitoring Zidovudine-Resistant HIV-1 in Resource-Limited Settings
Saeng-Aroon, S; Wichukchinda, N; Myint, L; Pathipvanich, P; Ariyoshi, K; Rojanawiwat, A; Matsuda, M; Sawanpanyalert, P; Sugiura, W; Auwanit, W
JAIDS Journal of Acquired Immune Deficiency Syndromes, 36(5): 1051-1056.

PDF (163)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B
Montes, B; Vergne, L; Peeters, M; Reynes, J; Delaporte, E; Segondy, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 35(4): 329-336.

PDF (356)
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
Grossman, Z; Hamouda, O; Hatzakis, A; Hemmer, R; Hoepelman, A; Horban, A; Korn, K; Kücherer, C; Leitner, T; Loveday, C; MacRae, E; Maljkovic, I; de Mendoza, C; Meyer, L; Nielsen, C; Op de Coul, EL; Ormaasen, V; Paraskevis, D; Perrin, L; Puchhammer-Stöckl, E; Ruiz, L; Salminen, M; Schmit, J; Schneider, F; Schuurman, R; Soriano, V; Stanczak, G; Stanojevic, M; Vandamme, A; Van Laethem, K; Violin, M; Wilbe, K; Yerly, S; Zazzi, M; Boucher, CA; van de Vijver, DA; Wensing, AM; Angarano, G; Åsjö, B; Balotta, C; Boeri, E; Camacho, R; Chaix, M; Costagliola, D; De Luca, A; Derdelinckx, I
JAIDS Journal of Acquired Immune Deficiency Syndromes, 41(3): 352-360.
10.1097/01.qai.0000209899.05126.e4
PDF (118) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002
Descamps, D; Chaix, M; André, P; Brodard, V; Cottalorda, J; Deveau, C; Harzic, M; Ingrand, D; Izopet, J; Kohli, E; Masquelier, B; Mouajjah, S; Palmer, P; Pellegrin, I; Plantier, J; Poggi, C; Rogez, S; Ruffault, A; Schneider, V; Signori-Schmück, A; Tamalet, C; Wirden, M; Rouzioux, C; Brun-Vezinet, F; Meyer, L; Costagliola, D
JAIDS Journal of Acquired Immune Deficiency Syndromes, 38(5): 545-552.

PDF (147)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Optimization of the Oligonucleotide Ligation Assay, a Rapid and Inexpensive Test for Detection of HIV-1 Drug Resistance Mutations, for Non-North American Variants
Beck, IA; Crowell, C; Kittoe, R; Bredell, H; Machaba, M; Willamson, C; Janssens, W; Jallow, S; van der Groen, G; Shao, Y; Jacob, M; Samuel, NM; de Rivera, IL; Ngo-Giang-Huong, N; Cassol, S; Alemnji, G; Frenkel, LM
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(4): 418-427.
10.1097/QAI.0b013e31817ed7d7
PDF (118) | CrossRef
Back to Top | Article Outline
Keywords:

HIV-1; clade C; efavirenz; non-nucleoside reverse transcriptase inhibitors

© 2003 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.